Hasebe Kenichi, Naiki Taku, Oda Risa, Etani Toshiki, Iida Keitaro, Sugiyama Yosuke, Nozaki Satoshi, Ando Ryosuke, Kawai Noriyasu, Nakanishi Ryoichi, Yasui Takahiro
Department of Nephro-urology, Nagoya City University, Graduate School of Medical Sciences, Japan.
Department of Oncology, Immunology and Surgery, Nagoya City University, Graduate School of Medical Sciences, Japan.
Urol Case Rep. 2018 Sep 3;21:52-55. doi: 10.1016/j.eucr.2018.08.024. eCollection 2018 Nov.
Cisplatin-based systemic chemotherapy is the gold standard for the treatment of patients with metastatic urothelial carcinoma (UC), which is a chemosensitive cancer. However, long-term survival has been deemed disappointing. We describe here a case of UC with solitary pulmonary metastasis who had successfully achieved long-term disease-free survival by combination of cisplatin-based chemotherapy and pulmonary metastasectomy. From the finding of this article, we propose that adjuvant chemotherapy may be considered as a viable option after metastasectomy in low volume pulmonary metastatic UC patients.
以顺铂为基础的全身化疗是转移性尿路上皮癌（UC）患者治疗的金标准，UC是一种对化疗敏感的癌症。然而，长期生存率一直不尽人意。我们在此描述一例孤立性肺转移的UC患者，通过顺铂为基础的化疗联合肺转移灶切除术成功实现了长期无病生存。基于本文的研究结果，我们建议对于低负荷肺转移的UC患者，在转移灶切除术后辅助化疗可被视为一种可行的选择。
